The Effect of Value Clarification Based on Meleis's Transition Theory on Menopausal Symptoms, Depression, Anxiety, Stress, and Quality of Life in Perimenopausal Women
Menopause is a life stage influenced not only by hormonal factors but also by psychological, social, and cultural factors. Symptoms such as hot flashes, sleep problems, and mood changes may occur, and their severity depends on how a woman perceives and copes with this period.
The study aims to examine the effects of the "Value Clarification" method based on Meleis Transition Theory on menopausal symptoms, depression, anxiety, stress, and quality of life in women during menopause.
調査の概要
詳細な説明
Menopause is a unique life event in a woman's life, influenced not only by physiological or hormonal factors, but also by cultural, psychological, and social factors. These changes that occur in a woman's life during menopause affect her quality of life, life satisfaction, and happiness.
Menopause is associated with vasomotor symptoms such as hot flashes and night sweats, musculoskeletal problems, sleep disturbances, urogenital changes, dyspareunia, sexual dysfunction, and mood swings. The number, severity, and impact of these symptoms on a woman's life depend on how she copes with this special period. A woman's perspective on the process is influenced by many factors. Being prepared for this period, not viewing it as the end of womanhood, and being aware of her own worth will reduce the degree to which she is negatively affected by menopause. Studies show that women who develop a positive attitude towards menopause experience milder symptoms. It can be said that there are limitations in the current system of care for the menopausal process in terms of changing the lack of information and negative perspectives on menopause.
In this context, this study aimed to examine the effects of Value Clarification, based on Meleis Transition Theory, on perimenopausal women's menopausal symptoms, depression, anxiety, stress levels, and menopause-specific quality of life.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Neslihan KAZAK SALTAN, PhD
- 電話番号：+905051059426
- メール：neslihankazak0369@hotmail.com
研究場所
-
-
Centre
-
Çorum、Centre、トルコ（Türkiye）、19100
- Corum Private Hospital
-
コンタクト：
- Neslihan KAZAK SALTAN, PhD
- 電話番号：05051059426
- メール：neslihankazak0369@hotmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Women who agree to participate in the study,
- Have at least a primary school education,
- Understand, read, and write Turkish,
- Have no communication barriers,
- Are between 45-55 years of age,
- Have started experiencing menstrual cycle irregularities or have not menstruated,
- Have experienced at least one menopausal symptom in the last 6 months (hot flashes, irritability, sleep problems, urogenital complaints, etc.),
- Are in the perimenopausal period according to the Straw Classification of Reproductive Aging in Women criteria,
- Women who have entered menopause naturally will be included in the study.
Exclusion Criteria:
- Women who:
- Use any complementary or alternative treatment methods (such as Reiki, phytoestrogens, acupressure),
- Use hypnotic or sedative medications,
- Have a diagnosed psychiatric illness,
- Have a gynecological problem causing menstrual irregularities,
- Have entered menopause as a result of any surgical operation such as a hysterectomy,
- Are receiving hormone replacement therapy will be excluded from the study.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Intervention group: Value clarification group
The value clarification exercise will be administered to the intervention group once a month for three months.
The results at the third and sixth months will be evaluated using scales.
|
The intervention group will be given written clarification of values.
After the pre-test, clarification will be applied once a month for 3 months, and the scales will be completed in the 3rd and 6th months.
|
|
アクティブコンパレータ：Control group: No intervention will be applied.
The control group will not receive the scales, but will be administered in parallel as a pre-test, at 3 months, and at 6 months.
|
The scales will be administered to the control group in parallel on the same dates.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in menopausal symptoms measured by the Menopausal Symptom Assessment Scale
時間枠：0-6 month
|
The value explanation method based on transition theory improves menopausal symptoms in women when applied to perimenopausal women.
The Menopausal Symptom Assessment Scale was developed to measure the severity of menopausal symptoms.
The scale, adapted into Turkish, consists of 11 items and 3 sub-dimensions.
These sub-dimensions are somatic complaints (items 1, 2, 3, and 11), psychological complaints (items 4, 5, 6, and 7), and urogenital complaints (items 8, 9, and 10).
The Likert-type scale, which includes menopausal complaints, uses the options: 0: None, 1: Mild, 2: Moderate, 3: Severe, and 4: Very severe.
The total score is calculated from the scores obtained from each item.
The lowest possible score is "0," and the highest is "44."
An increase in the total score indicates an increase in the severity of complaints and a negative impact on quality of life.
|
0-6 month
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in menopause-specific quality of life measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL)
時間枠：0-6 month
|
Value clarification based on transition theory given to perimenopausal women improves their menopause-specific quality of life. The scale, originally called the Menopause-Specific Quality of Life Questionnaire, was developed to assess the extent to which menopausal symptoms affect women's quality of life. The Turkish adaptation of is a Likert-type scale containing 29 questions. The scale consists of four sub-dimensions: Vasomotor (questions 1-3), Psychosocial (questions 4-10), Physical (questions 11-26), and Sexual (questions 27-29). Participants rate each symptom on a scale of 0-6, indicating its presence or absence. "NO" indicates the absence of the symptom, "PRESENT" or a score of 0 indicates the presence of the symptom, and a score of 1-6 indicates the severity and increasing degree of the existing problem. |
0-6 month
|
|
Changes in depression, anxiety, and stress levels that may be caused by mood swings during menopause were measured using the Depression Anxiety Stress Scale-21.
時間枠：0-6 month
|
Depression, anxiety, and stress levels will be assessed using the Depression Anxiety Stress Scale-21, a validated self-report questionnaire consisting of 21 items divided into three subscales: depression, anxiety, and stress (7 items each). Each item is scored on a 4-point Likert scale (0-3), where higher scores indicate greater symptom severity. Subscale scores are calculated by summing the relevant items, with possible scores ranging from 0 to 21 for each subscale. Severity thresholds are defined as follows: Depression: ≥14 indicates very severe depression Anxiety: ≥10 indicates very severe anxiety Stress: ≥17 indicates very severe stress |
0-6 month
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター：Nülüfer ERBİL, Prof. Dr.、Ordu university
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。